Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma - Concepedia

Concepedia

Publication | Open Access

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

DOI Full Paper Access

160

Citations

45

References

2008

Year

Martha Q. Lacy, Melissa Alsina, Rafaël Fonseca, M. Luisa Paccagnella, C. Melvin, Donghua Yin, Amarnath Sharma, Maurice Enriquez‐Sarano, Michaël Pollak, Sundar Jagannath,

Journal of Clinical Oncology

Abstract

These data indicate that CP-751,871 is well tolerated and may constitute a novel agent in the treatment of multiple myeloma.

References

	Year	Citations

Page 1